NASDAQ · CPIX

Cumberland Pharmaceuticals Inc.

$6.61 -$0.38 (-5.37%) 1D After hours

Key Metrics

$104.66M
Market cap
P/E · TTM
$45.16M
Revenue · TTM
−$4.18M
Net income
EPS · TTM $-0.27
Dividend yield
Free cash flow $7.40M
Beta · 1Y 0.71
EBITDA · TTM $240.54K
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 23
    The stock moved +27.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 23
  • Mar 18
    From its Feb 27 high, the share price fell 43%.

    Peak close $4.92 on Feb 27; trough close $2.80 on Mar 18. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -43%
  • Mar 4
    The stock moved -19.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$104.66M
Enterprise value
Shares outstanding15.0M
52-wk range$1.85 – $8.09
Avg volume · 20D449.7K
Net cash
Book value / share$1.42
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Cumberland Pharmaceuticals Inc.
IPO dateAug 11, 2009
Employees93

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.32
P/FCF14.14
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -8.9%
Net -9.3%
FCF 16.4%
ROE / ROIC -18.8% · -38.2%

Financial Health

Current ratio0.95
Quick ratio0.79
Debt / equity
Debt / EBITDA
Net cash
Working capital−$1.70M

Cash Flow · TTM

Operating CF $7.46M
Capex −$56.28K
Free cash flow $7.40M
Buybacks $76.87K
Dividends paid
Shareholder yield 0.1%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

1.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings